Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Fostamatinib disodium
Fostamatinib Disodium/ R935788 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Fostamatinib Disodium / R935788 | DRUG | R935788 tablets |
Inclusion Criteria: * Patients must be willing and able to give written informed consent by signing an IRB-approved Informed Consent Form prior to admission to this study. * Patients may be male or female, between the ages of 18 75. Men, if sexually active, must agree to use at least one medically ...
Fostamatinib Disodium is an investigational small molecule being studied for immune thrombocytopenic purpura, rheumatoid arthritis, T cell lymphoma, and warm antibody autoimmune hemolytic anemia. It is developed by Rigel Pharmaceuticals, Inc. (RIGL) and is currently in Phase 2 clinical development.
Fostamatinib Disodium is a kinase inhibitor, belonging to the -tinib class of drugs. It works by inhibiting spleen tyrosine kinase (Syk), which plays a role in immune signaling. This mechanism is being investigated for its potential effects in autoimmune and hematologic conditions.
Fostamatinib Disodium is developed by Rigel Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol RIGL. The company is conducting clinical trials to evaluate the drug's safety and efficacy in several indications.
Fostamatinib Disodium is in Phase 2 clinical development. While some completed trials were Phase 3, the overall development program is currently at Phase 2 stage. It is investigational and not yet approved by regulatory authorities.
Fostamatinib Disodium has been studied in several trials. NCT00798096 was a Phase 2 study in T cell lymphoma. NCT02076399 was a Phase 3 trial in immune thrombocytopenic purpura. NCT03764618 and NCT04138927 are Phase 3 studies in warm antibody autoimmune hemolytic anemia, with the latter currently enrolling by invitation.
Yes, Fostamatinib Disodium is also known as R935788. In clinical trials, it has been referred to by this alternative name, such as in the study NCT02076399, which evaluated R935788 in the treatment of persistent or chronic immune thrombocytopenic purpura.